Manitowoc to debut Potain self-erecting crane at Batimat

Manitowoc (MTW) reported Q2 2026 net sales of $594.9 million, up 10.3%, and adjusted EBITDA of $48.9 million, up 85.9%, with margin at 8.2%. Orders rose 56.1% to $708.7 million and backlog was $1,050.1 million. Full-year 2026 guidance was raised: net sales $2.3B-$2.4B and adjusted EBITDA $150M-$170M.

Manitowoc (NYSE:MTW) reported Q2 highlights including aftermarket non-new machine sales up 6% to $172 million, and trailing 12-month aftermarket sales of $706 million. July orders exceeded $200 million. The company cited tariff-related cash refunds of $26 million and raised 2026 guidance to net sales $2.3B-$2.4B and adjusted EBITDA $150M-$170M. Cash was $96M; liquidity $304M.

MANITOWOC CO INC (MTW) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 The Manitowoc Company Reports Strong Second-Quarter 2026 Results; Backlog Over $1.0 Billion, Adjusted EBITDA Improved 85.9% From the Prior Year, and Full Year Guidance Raised Second-Quarter 2026 Highlights • Orders of $708.7 million, up 56.1% year-over-year. Backlog

Bristol-Myers Squibb (BMY) reported positive Phase 3 trial results for Zenbexus in treating multiple myeloma, showing superior MRD-negative complete response rates. The data, published in The Lancet Oncology, validate BMS's CELMoD platform. BMY raised its 2026 revenue guidance to $49.0–$50.0 billion and non-GAAP EPS to $6.75–$7.00, despite increased R&D and commercialization costs. The company aims to offset legacy portfolio revenue decay with new growth drivers like Zenbexus.

Novo Nordisk (NVO) partnered with Nanexa AB to develop long-acting injectables for obesity and diabetes, extending dosing to monthly or quarterly. The deal includes €1.165B in payments. Novo reported 11% CER growth in adjusted operating profit for Q2 2026 and raised its full-year outlook. The collaboration aims to enhance patient retention and defend market share, but carries execution risks and upfront costs.

Meta launched the Meta Enterprise Platform, hiring MongoDB's former CEO, Chirantan Desai, to lead it. The platform includes four AI tools, competing with OpenAI and Microsoft. Meta plans to invest $600 billion in US AI infrastructure by 2028. The platform is not yet available in the UK or EU due to regulatory concerns.